Urology Doctors in Anderson, SC Accepting Medicare

6 Urology doctors found. Showing 1 - 6

Dr. Jeffrey A Larson, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2000 E Greenville St, Anderson, SC 29621 Phone: 864-716-6100    Fax: 864-716-6120

Dr. Raymond Kirk Seiler, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2000 E Greenville St, Suite 2900, Anderson, SC 29621 Phone: 864-716-6100    Fax: 864-716-6120

Dr. Dennis S. Whatley, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2000 E Greenville St, Suite 2900, Anderson, SC 29621 Phone: 864-716-6100    Fax: 864-716-6120

Dr. Vidal M Despradel, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2000 E Greenville St, Suite 5140, Anderson, SC 29621 Phone: 864-716-6100    Fax: 864-716-6120

Dr. Thomas J Serey, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2000 E Greenville St, Suite 5140, Anderson, SC 29621 Phone: 864-716-6100    Fax: 864-716-6120

Charles William Hinnant Jr., MD JD Urology Medicare: Accepting Medicare Assignments Practice Location: 112 Essex Dr, Anderson, SC 29621 Phone: 864-226-6131    Fax: 864-226-2320

News Archive

Watson Laboratories files ANDA to seek FDA's approval to market Nuvigil

Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 50 mg, 100 mg, 150mg, 200 mg, and 250mg strength armodafinil tablets prior to the expiration of patents owned by Cephalon France.

ImmunoCellular Therapeutics files a provisional patent application

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company's ICT-109 monoclonal antibody product candidate.

NCPA explains how PBM tools can reduce costs in Texas, other states

Texas and other states across the country could save billions in Medicaid without limiting access by transitioning to a more efficient and affordable pharmacy benefit model being used in Medicare and the commercial sector, the National Center for Policy Analysis announced in a new white paper, "Increasing the Cost-Effectiveness of Medicaid Drug Programs."

Study suggests natural UV radiation protects against coronavirus

A new study by scientists at the University of Edinburgh and published on the preprint server medRxiv* in July 2020 suggests an interesting link between ultraviolet A radiation and deaths due to COVID-19. While this is an observational study, which means that direct inferences cannot be drawn from this finding, it does, however, suggest better strategies for reducing the death rate due to COVID-19.

Metyrapone reduces brain's ability to re-record negative emotions associated with recalling painful memories

Recalling painful memories while under the influence of the drug metyrapone reduces the brain's ability to re-record the negative emotions associated with them, according to University of Montreal researchers at the Centre for Studies on Human Stress of Louis-H. Lafontaine Hospital.

Read more Medical News

› Verified 5 days ago